Advertisement

Drugs

, Volume 78, Issue 4, pp 513–519 | Cite as

Ertugliflozin: First Global Approval

  • Anthony MarkhamEmail author
AdisInsight Report

Abstract

Ertugliflozin (Steglatro™) is an orally active sodium glucose co-transporter type 2 inhibitor being developed by Merck and Pfizer as a treatment for type 2 diabetes mellitus (T2DM). Ertugliflozin as monotherapy and in combination with various other antidiabetic drugs was associated with improvements in glycaemic control and secondary outcome measures in the VERTIS phase III clinical trial program. Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet™) and ertugliflozin and sitagliptin (Steglujan™) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM. These products have also received a positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP). This article summarizes the milestones in the development of ertugliflozin leading to its first approval for T2DM.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process, both Merck and Pfizer were offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/31B99D70725E4EC0.

References

  1. 1.
    Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445–56.CrossRefPubMedGoogle Scholar
  2. 2.
    Merck & Co Inc. STEGLATRO™ (ertugliflozin) tablets, for oral use: prescribing information. 2017. http://www.merck.com/. Accessed 9 Feb 2018.
  3. 3.
    European Medicines Agency. CHMP summary of opinion: Steglatro (ertugliflozin). 2018. http://www.ema.europa.eu/. Accessed 9 Feb 2018
  4. 4.
    Merck & Co Inc. SEGLUROMET™ (ertugliflozin and metformin hydrochloride) tablets, for oral use: prescribing Information. 2017. http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
  5. 5.
    Merck & Co Inc. STEGLUJAN™ (ertugliflozin and sitagliptin) tablets, for oral use: prescribing Information. 2017. http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
  6. 6.
    European Medicines Agency. CHMP summary of opinion: Segluromet (ertugliflozin/metformin). 2018. http://www.ema.europa.eu/. Accessed 9 Feb 2018
  7. 7.
    European Medicines Agency. CHMP summary of opinion: Steglujan (ertugliflozin/sitagliptin). 2018.Google Scholar
  8. 8.
    Pfizer. FDA approves SGLT2 inhibitor SteglatroTM (ertugliflozin) and fixed-dose combination SteglujanTM (ertugliflozin and sitagliptin) for adults with type 2 diabetes 2017. http://www.pfizer.com/. Accessed 9 Feb 2018
  9. 9.
    Sahasrabudhe V, Saur D, Matschke K, et al. A phase 1, randomized, placebo- and active-controlled crossover study to determine the effect of single-dose ertugliflozin on QTc interval in healthy volunteers. Clin Pharmacol Drug Dev. 2018.  https://doi.org/10.1002/cpdd.421.PubMedGoogle Scholar
  10. 10.
    Sahasrabudhe V, Fediuk DJ, Matschke K, et al. Effect of food on the pharmacokinetics of ertugliflozin and its fixed dose combinations: ertugliflozin/sitagliptin and ertugliflozin/metformin [abstract no. PII-123]. Clin Pharmacol Ther. 2017;101(Suppl 1):S86–7.Google Scholar
  11. 11.
    Sahasrabudhe V, Terra SG, Hickman A, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017;57(11):1432–43.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kumar V, Sahasrabudhe V, Liang Y, et al. Effect of rifampin on the pharmacokinetics of ertugliflozin in healthy subjects [abstract no. PI-063]. Clin Pharmacol Ther. 2016;99(Suppl 1):S47.Google Scholar
  13. 13.
    Sahasrabudhe V, Kumar V, Matschke K, et al. Lack of a clinically meaningful pharmacokinetic interaction between ertugliflozin and glimepiride or simvastatin in healthy subjects [abstract no. PI-061]. Clin Pharmacol Ther. 2016;99(Suppl 1):S46–7.Google Scholar
  14. 14.
    Kumar V, Liang Y, Wei H, et al. Bioequivalence of ertugliflozin/metformin fixed-dose combination tablets and co-administration of respective strengths of individual components [abstract no. PII-071]. Clin Pharmacol Ther. 2017;101(Suppl. 1):S71.Google Scholar
  15. 15.
    Fediuk DJ, Matschke K, Liang Y, et al. Bioequivalence of ertugliflozin/sitagliptin fixed-dose combination tablets and co-administration of respective strengths of individual components. Clin Pharmacol Ther. 2017;101(S1):S63.Google Scholar
  16. 16.
    Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Frias J, Goldman A, Aronson R, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled type 2 diabetes despite diet and exercise: the 52-week VERTIS MONO study [abstract no. 1208-P]. Diabetes. 2017;66:A322–3.Google Scholar
  18. 18.
    Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017.  https://doi.org/10.1111/dom.13103.Google Scholar
  19. 19.
    Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2017.  https://doi.org/10.1007/s13300-017-0354-4.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9:253–68.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2017.  https://doi.org/10.1111/dom.13116.Google Scholar
  22. 22.
    Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2017.  https://doi.org/10.1111/dom.13194.PubMedCentralGoogle Scholar
  23. 23.
    Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2017.  https://doi.org/10.1007/s13300-017-0337-5.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17(8):805–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations